Now Playing
Opinion|Videos|December 21, 2023
Unmet Needs In Multiple Myeloma Management
Medical experts discuss unmet needs surrounding treatment of multiple myeloma.
Advertisement
Episodes in this series
This is a video synopsis/summary of a Peer Exchange featuring Joshua Richter, MD; Rafat Abonour, MD; Faith Davies, MD; and Amrita Krishnan, MD.
Experts Richter, Abonour, Davies, and Krishnan discuss the current landscape of frontline treatment options for multiple myeloma. Abonour emphasizes the challenges in managing high-risk patients and highlights the need for tailored approaches. Other essential topics the panel discusses include the role of consolidation therapy and the significance of minimal residual disease testing in treatment decisions. Richter and Davies focus on the increasing prevalence of myeloma, with approximately 35,000 new cases in the US annually. The racial disparities in myeloma incidence, particularly among African Americans, are acknowledged. The experts stress the importance of addressing unmet needs, including a focus on achieving cures and optimizing treatment for older and frail patients. The discussion sets the stage for exploring emerging therapies and trends at the 2023 American Society of Hematology Annual Meeting and Exposition (ASH 2023).
Video synopsis is AI-generated and reviewed by AJMC® editorial staff.
Advertisement
Related to this article
The National Comprehensive Cancer Network update on mantle cell lymphoma puts covalent BTK inhibitors, MRD testing, and TP53 sequencing at the center of frontline care, while adding pirtobrutinib and a pair of CAR T-cell therapies for disease that progresses on a BTK inhibitor.
These findings demonstrate substantial but variable use of community care consultations for specialty care among patients with diabetic foot ulcers within the Veterans Health Administration.
Two posters report 3.9% first-year GLP-1 discontinuation and a 5-day median time to first fill under pharmacist-led care.
CDC's Jane Henley, MSPH, explains what's behind falling lung cancer deaths and why 4 in 5 eligible adults still aren't getting screened.
The regulatory decisions reflect how advances in biomarkers and molecular medicine are reshaping both diagnosis and treatment.
Measles cases hit a year high. Here's what payers need to know about outbreak costs, MMR coverage, and plans to split the vaccine
As peptides go mainstream, the FDA's shifting rules and a fractured state patchwork leave patients navigating a largely unregulated gray market.
Community oncologists cited prior authorization as a care barrier, even as AI adoption doubled in 2026, according to the Oncology Care Index.
Advertisement
Advertisement
Trending on AJMC
1
Peptide Regulation Debate Intensifies After FDA Advisory Panel's Controversial Vote
2
Opposing Sides of 340B Debate Converge on Data Clearinghouse, Patient Definition
3
Health System Pharmacies Keep Patients on GLP-1 Therapy
4
Community Oncologists Ready to Innovate, but Barriers Remain
5